Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70421 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Changyuan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Frailty, Healthcare Disparities. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.
Themen: Diabetes mellitus, Gerontologische Pflege
Abstract (Originalsprache)
Background
Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear.
Methods
This observational study analysed data from adults registered in primary care during 2023, using the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. Eligibility for SGLT2 inhibitor treatment was determined based on the Dutch College of General Practitioners (NHG) guideline for T2DM. Prescription rates were assessed across demographics, comorbidities, and preceding medication use. Multivariable logistic regression models were used to assess the association of age and identify factors associated with SGLT2 inhibitor prescriptions.
Results
Among 10 241 adults with T2DM, 41% ( n = 4223) were eligible for SGLT2 inhibitor prescription. The prescription rate in the overall population was 15.2% and among eligible people was 25.5%. In people eligible for SGLT2 inhibitors, prescription rates were markedly lower with increasing age, with 37.6% in those aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Division of Health, University of Waikato, Hamilton, New Zealand.
- Waikato Regional Diabetes Service, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: Changyuan Yang, Jung-Im Shin, Priya Vart
Förderung
- NIDDK NIH HHS
Zitieren
APA
Yang, C., Denig, P., Chepulis, L., Paul, R. G., Shin, J. I., Gansevoort, R. T., & Vart, P. (2026). Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70421
Vancouver
Yang C, Denig P, Chepulis L, Paul RG, Shin JI, Gansevoort RT, et al. Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70421
BibTeX
@article{Yang2026,
author = {Yang, Changyuan and Denig, Petra and Chepulis, Lynne and Paul, Ryan G and Shin, Jung-Im and Gansevoort, Ron T and Vart, Priya},
title = {Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70421}
}
EUVIMED